Page last updated: 2024-11-02

pioglitazone and Ischemia

pioglitazone has been researched along with Ischemia in 10 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Ischemia: A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.

Research Excerpts

ExcerptRelevanceReference
"In a nondiabetic murine model of hindlimb ischemia, a single intramuscular injection of pioglitazone-incorporated NP (1 µg/kg) into ischemic muscles significantly improved the blood flow recovery in the ischemic limbs, significantly increasing the number of CD31-positive capillaries and α-smooth muscle actin-positive arterioles."7.78Nanoparticle-mediated delivery of pioglitazone enhances therapeutic neovascularization in a murine model of hindlimb ischemia. ( Egashira, K; Kim-Mitsuyama, S; Matoba, T; Nagahama, R; Nakano, K; Sunagawa, K, 2012)
"To observe effects of the drug pioglitazone on expression of hypoxia inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) in diabetic rats with hindlimb ischemia, and explore the role of pioglitazone in angiogenesis after ischemia and its possible mechanism."3.80Effect of pioglitazone on expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in ischemic hindlimb of diabetic rats. ( Bai, SJ; Gao, X; Ye, XM; Zhang, J; Zhang, M, 2014)
"Pharmacologic delay with pioglitazone can improve extended perforative flap viability through increasing ischemia-induced angiogenesis and choke vessels vasodilation in rat models."3.80[EFFECT OF PHARMACOLOGIC DELAY WITH PIOGLITAZONE ON EXTENDED PERFORATOR FLAP SURVIVAL IN A RAT MODEL]. ( Chen, S; Gao, W; Li, J; Li, Z; Lin, D; Yan, H, 2014)
" In this study, we investigated whether TZDs affect onset, spectral characteristics, and mortality of ischemic ventricular fibrillation (VF) and whether such effects are recapitulated by a non-selective K(ATP) blocker (glyburide) or a mitochondrial K(ATP) blocker (5-hydroxydecanoate)."3.78Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs. ( Greyson, CR; Lu, L; Reiter, MJ; Sarraf, M; Schwartz, GG; Ye, S, 2012)
"In a nondiabetic murine model of hindlimb ischemia, a single intramuscular injection of pioglitazone-incorporated NP (1 µg/kg) into ischemic muscles significantly improved the blood flow recovery in the ischemic limbs, significantly increasing the number of CD31-positive capillaries and α-smooth muscle actin-positive arterioles."3.78Nanoparticle-mediated delivery of pioglitazone enhances therapeutic neovascularization in a murine model of hindlimb ischemia. ( Egashira, K; Kim-Mitsuyama, S; Matoba, T; Nagahama, R; Nakano, K; Sunagawa, K, 2012)
"By using a hindlimb ischemia murine model, in this study we have found that pioglitazone restores the blood flow recovery and capillary density in ischemic muscle of diabetic mice and that this process is associated with increased expression of Vascular Endothelial Growth Factor (VEGF)."3.75Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARgamma stimulation. ( Arena, V; Biscetti, F; De Angelis, G; Flex, A; Ghirlanda, G; Iuliano, L; Pecorini, G; Rizzo, P; Stigliano, E; Straface, G, 2009)
"Pioglitazone treatment was associated with reductions in limb perfusion at 2 weeks measured by contrast-enhanced ultrasound and Tc(99m)-Sestamibi SPECT-CT."1.40Pioglitazone inhibits HIF-1α-dependent angiogenesis in rats by paracrine and direct effects on endothelial cells. ( Dromparis, P; McMurtry, MS; Michelakis, ED; Paulin, R; Proctor, S; Sutendra, G, 2014)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (30.00)29.6817
2010's7 (70.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dromparis, P1
Sutendra, G1
Paulin, R1
Proctor, S1
Michelakis, ED1
McMurtry, MS1
Zhang, M1
Gao, X1
Bai, SJ1
Ye, XM1
Zhang, J1
Li, Z2
Gao, W1
Chen, S1
Li, J1
Yan, H1
Lin, D1
Biscetti, F1
Straface, G1
Arena, V1
Stigliano, E1
Pecorini, G1
Rizzo, P1
De Angelis, G1
Iuliano, L1
Ghirlanda, G1
Flex, A1
Higuchi, A1
Ohashi, K1
Shibata, R1
Sono-Romanelli, S1
Walsh, K1
Ouchi, N1
Sarraf, M1
Lu, L1
Ye, S1
Reiter, MJ1
Greyson, CR1
Schwartz, GG1
Nagahama, R1
Matoba, T1
Nakano, K1
Kim-Mitsuyama, S1
Sunagawa, K1
Egashira, K1
Sheng, CC1
Hong, CC1
Huang, PH1
Sata, M1
Nishimatsu, H1
Sumi, M1
Hirata, Y1
Nagai, R1
Matsuhashi, N1
Watanabe, K1
Kanamori, H1
Ohnishi, S1
Omata, M1

Other Studies

10 other studies available for pioglitazone and Ischemia

ArticleYear
Pioglitazone inhibits HIF-1α-dependent angiogenesis in rats by paracrine and direct effects on endothelial cells.
    Journal of molecular medicine (Berlin, Germany), 2014, Volume: 92, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Cell Line; Endothelial Cells; Hindlimb; Humans; Hypoxia-Inducible

2014
Effect of pioglitazone on expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in ischemic hindlimb of diabetic rats.
    European review for medical and pharmacological sciences, 2014, Volume: 18, Issue:9

    Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diab

2014
[EFFECT OF PHARMACOLOGIC DELAY WITH PIOGLITAZONE ON EXTENDED PERFORATOR FLAP SURVIVAL IN A RAT MODEL].
    Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery, 2014, Volume: 28, Issue:6

    Topics: Angiogenesis Inducing Agents; Angiography; Animals; Blood Flow Velocity; Graft Survival; Hypoglycemi

2014
Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARgamma stimulation.
    Cardiovascular diabetology, 2009, Sep-08, Volume: 8

    Topics: Anilides; Animals; Benzophenones; Blood Flow Velocity; Blood Glucose; Collateral Circulation; Diabet

2009
Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism.
    Arteriosclerosis, thrombosis, and vascular biology, 2010, Volume: 30, Issue:1

    Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Diabetic Retinopathy; Hypoglycemic Agents; Isch

2010
Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs.
    Cardiovascular drugs and therapy, 2012, Volume: 26, Issue:3

    Topics: Animals; Anti-Arrhythmia Agents; Coronary Vessels; Death, Sudden, Cardiac; Decanoic Acids; Female; G

2012
Nanoparticle-mediated delivery of pioglitazone enhances therapeutic neovascularization in a murine model of hindlimb ischemia.
    Arteriosclerosis, thrombosis, and vascular biology, 2012, Volume: 32, Issue:10

    Topics: Anilides; Animals; Fibroblast Growth Factor 1; Hindlimb; Humans; Injections, Intramuscular; Ischemia

2012
Mixing of the old with the new: nanoparticle-mediated pioglitazone delivery to enhance therapeutic neovascularization.
    Arteriosclerosis, thrombosis, and vascular biology, 2012, Volume: 32, Issue:10

    Topics: Animals; Hindlimb; Humans; Ischemia; Nanoparticles; Neovascularization, Physiologic; Pioglitazone; P

2012
Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2008, Volume: 62, Issue:1

    Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Endothelium, Vascular; Hypoglycemic Agen

2008
PPARgamma agonists for intestinal ischaemia.
    Lancet (London, England), 2001, Jul-07, Volume: 358, Issue:9275

    Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents;

2001